The Toxicology Meeting That’s Different – Made for Biotech and Pharma Leaders
The Investigative & Preclinical Toxicology Summit (May 12-14 | Boston, MA) is set to redefine toxicology meetings for biotech and pharmaceutical professionals. Unlike traditional academic conferences, this summit provides a platform where leaders in drug safety pressure-test ideas, share real-world successes, and drive smarter safety decisions.
Scheduled to bring together decision-makers shaping drug development, the summit offers real-time opportunities to debate, challenge, and get actionable answers.
Why This Meeting Stands Out
- Biotech & Pharma Focus: Sessions are 100% tailored to investigative and preclinical toxicology in industry settings.
- Interactive Format: Panels, roundtables, poster sessions, and open Q&A encourage discussion, not just lectures.
- Scientist-Led: Designed by scientists with real development accountability, ensuring practical takeaways for attendees.
Learn from the Experts Shaping the Future of Toxicology:
- Anna Kopec, Director, Investigative Toxicology, Pfizer – Driving cross-industry collaboration through the IQ MPS Affiliate to accelerate regulatory-ready in vitro NAM adoption.
- Marc DeCristofaro, Director, Medicinal Safety, Daiichi Sankyo & Colin Choi, Associate Scientific Director, Biogen – Practical strategies for navigating global regulatory expectations and building IND-ready preclinical tox packages.
- Mathew Martin, Executive Director & Global Head, Computational Safety Sciences, Pfizer – Expanding data foundations to unlock predictivity and regulatory confidence for NAMs and AI.
- Ronnie Yeager, Research Fellow, Emerging Therapeutic Platforms, AbbVie – Real-world case study using lung MPS models to evaluate ADC-induced ILD risk.
- Natalie Ketter, Global Head, Early Safety Sciences, Boehringer Ingelheim – Integrating in silico insights with tailored in vitro approaches to prioritize safer targets and candidates earlier.
📌 See the Full Speaker Faculty Here.
About the Summit
If your work sits at the intersection of model selection, translational science, and IND confidence, this is the essential forum to benchmark strategies, separate innovation from hype, and accelerate safer drug development.
For more information, visit Summit Homepage.